Grant Pickering, Vaxcyte CEO
Vaxcyte to raise $500M from stock offering for PhIII study of pneumococcal vaccine
Vaxcyte is set to raise $500 million via a stock sale to fund its work on a pneumococcal vaccine it hopes can supplant Pfizer’s Prevnar …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
